Drug

AbbVie's RINVOQ Wins NMPA Approval for Severe Alopecia Areata – Ninth Indication in China Three Months After EU Clearance
AbbVieNYSE: ABBV

AbbVie’s RINVOQ Wins NMPA Approval for Severe Alopecia Areata – Ninth Indication in China Three Months After EU Clearance

AbbVie Inc. (NYSE: ABBV) announced that China's National Medical Products Administration (NMPA) has approved RINVOQ (upadacitinib extended‑release tablets, 15 mg and 30 mg, once daily) for the treatment of adults…

CSPC Pharmaceutical's Trispecific Antibody SYS6088 Wins NMPA Clinical Trial Approval – PD‑1/VEGFA/CTLA‑4 Candidate Targets Advanced and Metastatic Solid Tumors

CSPC Pharmaceutical’s Trispecific Antibody SYS6088 Wins NMPA Clinical Trial Approval – PD‑1/VEGFA/CTLA‑4 Candidate Targets Advanced and Metastatic Solid Tumors

Qilu Pharmaceutical's QLS2401 Wins CDE Clinical Trial Approval – Trispecific PSMA/STEAP1/CD3 T‑Cell Engager Targets Metastatic Castration‑Resistant Prostate Cancer

Qilu Pharmaceutical’s QLS2401 Wins CDE Clinical Trial Approval – Trispecific PSMA/STEAP1/CD3 T‑Cell Engager Targets Metastatic Castration‑Resistant Prostate Cancer

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Ab&b Bio-Tech's Trivalent Influenza Vaccine Wins NMPA Nod for All Ages
Ab&B Bio-TechHKG: 2627

Ab&b Bio-Tech’s Trivalent Influenza Vaccine Wins NMPA Nod for All Ages

Sanofi Rezurock Wins EU Backing for Graft‑Versus‑Host Disease
NASDAQ: SNYSanofi

Sanofi Rezurock Wins EU Backing for Graft‑Versus‑Host Disease

CMS-D017 Gets NMPA Nod for PNH Clinical Trial
China Medical SystemClinical trial approval / initiation

CMS-D017 Gets NMPA Nod for PNH Clinical Trial

J&J AKEEGA Gets CHMP Nod for BRCA-Mutated Prostate Cancer
CancerJohnson & Johnson

J&J AKEEGA Gets CHMP Nod for BRCA-Mutated Prostate Cancer

Show More